

Calcif Tissue Int (2013) 93:101–120  
 DOI 10.1007/s00223-013-9758-y

REVIEW

## Quality of Life in Sarcopenia and Frailty

René Rizzoli · Jean-Yves Reginster · Jean-François Arnal · Ivan Bautmans ·  
 Charlotte Beaudart · Heike Bischoff-Ferrari · Emmanuel Biver · Steven Boonen ·  
 Maria-Luisa Brandi · Arkadi Chines · Cyrus Cooper · Sol Epstein ·  
 Roger A. Fielding · Bret Goodpaster · John A. Kanis · Jean-Marc Kaufman ·  
 Andrea Laslop · Vincenzo Malafarina · Leocadio Rodriguez Mañas ·  
 Bruce H. Mitlak · Richard O. Oreffo · Jean Petermans · Kieran Reid ·  
 Yves Rolland · Avan Aihie Sayer · Yannis Tsouderos · Marjolein Visser ·  
 Olivier Bruyère

Received: 13 March 2013 / Accepted: 27 March 2013 / Published online: 5 July 2013  
 © Springer Science+Business Media New York 2013

**Abstract** The reduced muscle mass and impaired muscle performance that define sarcopenia in older individuals are associated with increased risk of physical limitation and a variety of chronic diseases. They may also contribute to clinical frailty. A gradual erosion of quality of life (QoL) has been evidenced in these individuals, although much of this research has been done using generic QoL instruments, particularly the SF-36, which may not be ideal in older

populations with significant comorbidities. This review and report of an expert meeting presents the current definitions of these geriatric syndromes (sarcopenia and frailty). It then briefly summarizes QoL concepts and specificities in older populations and examines the relevant domains of QoL and what is known concerning QoL decline with these conditions. It calls for a clearer definition of the construct of disability, argues that a disease-specific QoL instrument

J.-Y. R. has received consulting fees or paid advisory boards for Servier, Novartis, Negma, Lilly, Wyeth, Amgen, Glaxo SmithKline, Roche, Merckle, Nycomed, NPS, Theramex, and UCB; lecture fees from Merck Sharp and Dohme, Lilly, Rottapharm, IBSA, Genevrier, Novartis, Servier, Roche, Glaxo SmithKline, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Theramex, Nycomed, Novo-Nordisk, and Nolver; Grant support from Bristol Myers Squibb, Merck Sharp and Dohme, Rottapharm, Teva, Lilly, Novartis, Roche, Glaxo SmithKline, Amgen, and Servier. A. C. owns stock in Pfizer. C. C. has a consultant/advisory role to Amgen, Glaxo SmithKline, ABBH, Merck Sharpe and Dohme, Eli Lilly, Pfizer, Novartis, Servier, Medtronic, and Roche. R. F. has had remuneration, has played a consultant/advisory role, and has stock ownership of or funding from Eli Lilly, Dairy Management, Abbott, Pronutrim, Bristol Myers Squibb, Cytokinetics, and Nestec. B. G. has received remuneration from Abbott Nutrition. J. K. has worked with and received funding from many companies and nongovernmental organizations dealing with skeletal metabolism including research funding from the Health Technology Assessment NHS R&D HTA Programme of the UK. B. M. is an employee of and owns stock in Eli Lilly. K. R. has a consultant/advisory role to Eli Lilly. Y. R. has received funding from Eli Lilly, Merck Sharpe and Dohme, Fabre, and Servier. A. S. has received remuneration from Abbott Nutrition, Servier, and Nestle and funding from Glaxo SmithKline. O. B. has received grant support from IBSA, Merck Sharp and Dohme, Nutraveris, Novartis, Pfizer, Rottapharm, Servier, and Theramex; lecture fees from IBSA, Rottapharm, Servier, and SMB; reimbursements for attending meetings from IBSA, Merck Sharp and Dohme, Novartis, Pfizer, Rottapharm, Servier, and Theramex. All other authors have stated that they have no conflict of interest.

R. Rizzoli (✉) · E. Biver  
 Service of Bone Diseases, Geneva University Hospitals  
 and Faculty of Medicine, Geneva, Switzerland  
 e-mail: rene.rizzoli@unige.ch

J.-Y. Reginster · C. Beaudart · O. Bruyère  
 Department of Public Health, Epidemiology and Health  
 Economics, University of Liege, Liege, Belgium

J.-F. Arnal  
 INSERM Research Unit 1048, Faculty of Medicine, University  
 of Toulouse and CHU of Toulouse, Toulouse, France

I. Bautmans  
 Gerontology and Frailty in Ageing Research Department,  
 Vrije Universiteit, Brussels, Belgium

H. Bischoff-Ferrari  
 Centre on Aging and Mobility, University of Zurich,  
 Zurich, Switzerland

S. Boonen  
 Division of Geriatric Medicine & Center for Metabolic  
 Bone Diseases, Department of Internal Medicine,  
 Leuven University Hospital, Leuven, Belgium

M.-L. Brandi  
 Department of Internal Medicine, University of Florence,  
 Florence, Italy

for sarcopenia/frailty would be an asset for future research, and discusses whether there are available and validated components that could be used to this end and whether the psychometric properties of these instruments are sufficiently tested. It calls also for an approach using utility weighting to provide some cost estimates and suggests that a time trade-off study could be appropriate.

**Keywords** Age · Aging · Muscle weakness · Quality of life · Malnutrition

## Introduction

The term “sarcopenia” helped to spotlight this common muscle wasting condition when it was introduced in 1989 [1]. Since then, its definition has seen a number of modifications, moving from a biogerontological concept to a clinical condition, which focuses more on the pronounced muscular deficits that impact functional independence and the possible roles of extrinsic factors, such as lifestyle, nutrition, and concomitant disease [2]. In 2010, two articles were published, and a third the following year, that proposed consensus diagnosis criteria [3–5]. Their conclusions were similar and should serve as a base for future research.

The term “frailty” represents a well-recognized clinical syndrome, yet it is defined by a number of different classification criteria [6, 7]. A key element underlying most frailty definitions is sarcopenia (i.e., skeletal muscle loss) [7, 8]. Frail older people are particularly vulnerable to

external stressors and less able to resist the mental and physical challenges after a destabilizing event, although it is now clear that both frailty and sarcopenia carry a prognosis of (rapid) further functional decline with a higher risk of comorbidity and increasing disability (higher risks of falls, hospitalization, institutionalization, and death) than in the older population as a whole [9–11]. Thus, one of the major challenges of geriatric medicine is to recognize these conditions as soon as possible and to halt (or slow) the downward spiral of increasing comorbidity and frailty [7, 12].

That the quality of life (QoL) declines in frailty is intuitively evident, and there are good indications that this is also the case for sarcopenia. However, in the absence of specific QoL tools and without a clear conceptual framework of QoL in these patients, an important element in the characterization and follow-up of these conditions seems to be missing. Since comorbidities are very frequent in both, attributing QoL to the core condition remains a challenge.

We describe herein the conclusions that were made during a discussion session in November 2012 on a possible QoL assessment in sarcopenia and frailty.

## Definitions

### Sarcopenia

The three consensus papers which have published a definition of sarcopenia were written under the auspices of,

A. Chines  
Amgen Inc., Thousand Oaks, CA, USA

C. Cooper · A. A. Sayer  
MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

S. Epstein  
Division of Endocrinology, Mount Sinai School of Medicine, New York, NY, USA

R. A. Fielding  
Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA

B. Goodpaster  
Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

J. A. Kanis · K. Reid  
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK

J.-M. Kaufman  
Department of Endocrinology, Ghent University Hospital, Ghent, Belgium

A. Laslop  
Austrian Agency for Health and Food Safety, Vienna, Austria

V. Malafarina  
Department of Geriatrics, Hospital San Juan de Dios, Pamplona, Spain

L. R. Mañas  
Department of Geriatrics, University Hospital of Getafe, Madrid, Spain

B. H. Mitlak  
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

R. O. Oreffo  
Bone and Joint Research Group, Institute of Developmental Sciences, University of Southampton Medical School, Southampton, UK

J. Petermans  
Service of Geriatrics, CHU of Liege, Liege, Belgium

Y. Rolland  
Gérontopôle of Toulouse, University of Toulouse III, CHU Purpan, Toulouse, France

respectively, the European Working Group on Sarcopenia in Older People (EWGSOP) [3], the European Society for Clinical Nutrition and Metabolism Special Interest Groups (ESPEN-SIG) [4], and the International Working Group on Sarcopenia (IWGS) [5]. The consensus definitions were as follows:

- The presence of low skeletal muscle mass and either low muscle strength (e.g., handgrip) or low muscle performance (e.g., walking speed or muscle power); when all three conditions are present, severe sarcopenia may be diagnosed (EWGSOP).
- The presence of low skeletal muscle mass and low muscle strength (which they advised could be assessed by walking speed) (ESPEN-SIG).
- The presence of low skeletal muscle mass and low muscle function (which they advised could be assessed by walking speed) and “that [sarcopenia] is associated with muscle mass loss alone or in conjunction with increased fat mass” (IWGS).

Thus, the EWGSOP consensus, by separating muscle strength and muscle performance, allows for a slightly broader definition and provides a classification of a severe condition.

A fairly long-running debate in this field is whether or not to apply the term “dynapenia” to the age-related loss of muscle strength and limiting sarcopenia to age-related loss of muscle mass [13]. Although the two processes may occur simultaneously in some individuals, they do not necessarily overlap and may be the result of different pathophysiological processes. The EWGSOP consensus authors, however, seem to be of the opinion that since “sarcopenia” is already a fairly well-known term, the introduction of another may lead to confusion [3].

The EWGSOP consensus also discussed the frailty concept and its overlap with sarcopenia. It recognized, as others have done [6, 14], that frailty is characterized by deficits in multiple organ systems, i.e., psychological, cognitive, and/or social functioning, as well as physical limitations.

---

Y. Tsouderos  
Institut de Recherches Internationales Servier, Suresnes, France

M. Visser  
Department of Health Sciences, VU University, Amsterdam,  
The Netherlands

M. Visser  
Department of Epidemiology and Biostatistics, EMGO Institute  
for Health and Care Research, VU University Medical Center,  
Amsterdam, The Netherlands

## Frailty

While a theoretical definition of “frailty” could be the lack of functional reserve [15], no single operational definition has met with widespread acceptance and consensus meetings have yet to offer a solution [6, 16]. Widely used operational (phenotypic) definitions are those suggested by Rockwood and colleagues in 1999 [17] and Fried and colleagues in 2001 [18]. The Rockwood definition, with four classes of disability, is considered by some experts in the field to be flawed by using a combination of frailty and disability and considering frailty as a risk factor for disability. The Fried definition cites the accumulation of deficits in five domains: unintended weight loss, muscle weakness (grip strength), self-reported exhaustion, slow walking speed (i.e., low gait speed), and low physical activity. A total of two deficits indicates a prefrail condition, and a total of three or more deficits indicates frailty. More recent frailty scales have been proposed, and some of these use continuous variables [19] or extend the scale with social and psychological measures [20–22]. The majority of definitions of frailty include loss of skeletal muscle as a component [8], and it is the musculoskeletal component of frailty as the phenotype that most frequently comes to the attention of health-care professionals [6].

## Sarcopenic Obesity

The term “sarcopenic obesity” has been used to describe a subgroup of sarcopenic individuals with a high percentage of body fat. This subgroup has been recognized for some time as having a particularly high risk of adverse outcomes [23]. The condition is characterized by, in addition to low lean muscle mass or low muscle performance, excess energy intake, low physical activity, low-grade inflammation, and insulin resistance [3, 23].

## Cachexia

This describes a severe wasting condition that is seen in chronic disease states such as cancer, congestive cardiomyopathy, and end-stage renal disease. This was the subject of the ESPEN-SIG consensus report [4], and the definitions presented therein and previously [24] were endorsed by the EWGSOP. Cachexia is associated with inflammation and frequently with insulin resistance and anorexia. It may therefore be viewed as a complex metabolic syndrome invoked by the underlying illness. While most cachectic individuals also have sarcopenia; sarcopenic individuals, unless they have an increased inflammatory status and/or impaired carbohydrate, protein, or lipid metabolism, are not considered as having cachexia.

## Diagnostic Criteria

### Sarcopenia

The consensus papers concurred on the use of a T-Score-based cutoff for lean (skeletal) muscle mass (appendicular lean mass [aLM]) divided by height squared with a threshold of  $\geq 2$  standard deviations (SD) below the mean measured in young adults in a reference population. The EWGSOP suggested that muscle mass could be determined by computed tomography (CT scan) or magnetic resonance imaging (MRI, the gold standards) or dual-energy X-ray absorptiometry (DXA, the preferred alternative); the IWGS pronounced for DXA; and the ESPEN-SIG gave no indication. Using the Rosetta study for the reference population [25] and using DXA for mass measurement, this T-Score method gives values of  $\leq 7.3 \text{ kg/m}^2$  for men and  $\leq 5.5 \text{ kg/m}^2$  for women.

It seems relevant, however, that aLM is also indexed for body fat mass (e.g., on the residuals from a regression analysis). This approach, used in the Health, Aging, and Body Composition (Health ABC) study [26], was found to give a better identification of overweight or obese sarcopenic individuals and better associations with impaired lower extremity function. Other recent research investigations, which have used DXA to measure body tissue mass, applied a definition of obesity as body fat mass greater than the 60th percentile of a “normal” population (typically 28 % body fat in men and 40 % in women) [27, 28].

The second criterion for sarcopenia in all three consensus papers was usual gait speed. The most favored assessment seems to be on a 4 m course, with a reference speed of either 0.8 m/s (suggested by EWGSOP and ESPEN-SIG) or 1 m/s (IWGS), where the inferior values are indicative of sarcopenia. Further research will be required to more closely define this threshold, with perhaps a small difference between genders. In a recent cross-sectional study [29] of 3,145 older adults in England (aged  $\geq 65$  years, 46 % men) it was found that the mean walking speed was 0.9 m/s in men and 0.8 m/s in women. The conclusion of this study, which examined walking speed in the context of traffic collisions and socioeconomic factors, was that the national standard of normal walking speed for pedestrian crossings of 1.2 m/s was too high for this segment of the population.

A third criterion (suggested by the EWGSOP) was low muscle strength, which, it was suggested, can be most conveniently measured using a handgrip dynamometer (with a certain preference for the Jamar model).

Table 1 gives the cutoffs for the more widely used and well-validated criteria for lean muscle mass determined by DXA, muscle strength, and muscle performance by gait speed.

### Frailty

Using the definition of “frailty” proposed by Fried, there remains heterogeneity of assessment methods and of the cutoff values for a positive diagnosis. Table 2 shows a small sample of trials that have analyzed their respective populations according to these criteria; the reference study by Fried appears in the first column. It may be seen that a number of more or less subtle differences are evident, from the methods of correction of parameters for body size or gender to the use of subjective reports in place of objective measurements. In the examples shown, the percentages of frail and prefrail individuals show some similarities despite the methodological differences (4–11 % for frail and 37–55 % for prefrail). Others have found, however, quite heterogeneous results when different frailty criteria are applied, with the prevalence in a sample population ranging 33–88 % [33].

### The Need for Simplicity and Consistency in Measurement and Terminology

The EWGSOP consensus paper interestingly provides details and suggested threshold values for a number of other measurement techniques, which do provide valid performance assessments. Some are more widely used, such as short physical performance battery (SPPB) and the “timed get-up-and-go” (TGUG) protocol; others are less so. Here, and elsewhere in the literature, it can be seen that various methodological debates exist, such as whether muscle power as a measure provides greater prognostic value than muscle strength, whether grip strength is better assessed on the dominant hand or the nondominant hand, and whether the recorded value should be the best of three tries, meaned, or summed [38, 39].

**Table 1** Frequently used cutoff values for a selection of diagnostic criteria for sarcopenia

	Men	Women
Skeletal muscle mass		
SMI by DXA [25]	$<7.26 \text{ kg/m}^2$	$<5.45 \text{ kg/m}^2$
Muscle strength		
Handgrip strength [30]	$<30 \text{ kg}$	$<20 \text{ kg}$
Muscle performance		
Gait speed on 4 m course [31]	$<1.0 \text{ m/s}$	
SPPB [32]	$\leq 8$	

DXA dual-energy X-ray absorptiometry, SMI skeletal muscle mass index, where appendicular skeletal muscle mass is standardized using the square of the individuals’ height; SPPB short physical performance battery, summation of scores for balance, gait speed, and chair stand (max score = 12)

**Table 2** Components of frailty and a selection of frequently used diagnostic criteria

Components of frailty	Cardiovascular health study (2001) [18] (n = 1,741)	InChianti study (2006) [34] (n = 827)	Survey of health, aging and retirement (SHARE, 2010) [35] (n = 18,227)	Women's health and aging studies (2010) [36] (n = 786)	TROPOS and SOTI (2011) [37] (n = 5,082)
Unintentional weight loss	≥5 % loss of body weight in prior year	>4.5 kg self-reported unintentional weight loss in previous year	A negative response to the question "What has your appetite been like?"	≥10 % weight loss since age 60 until exam	≥5 % loss of body weight in prior year
Self-reported exhaustion	A positive response to either (CES-D) statement: I felt that everything I did was an effort (ii) I could not get going	A positive response to either (CES-D) statement: (i) I felt that everything I did was an effort (ii) I could not get going	A positive response to the statement: (i) In the last month, I have too little energy to do things I want to do	A report of any of the following: (i) low usual energy level (≤3, range 0–10), (ii) felt unusually tired in last month, or (iii) felt unusually weak in the past month	A response of "most or all the time" to either (SF-36–Vitality) question: (i) Did you feel worn out? (ii) Did you feel tired ?
Low physical activity	270 on activity scale (18 items)	Self-reported physical activity during the home interview	A response of "one or three times a month" to the question (i) "How often do you engage in activities that require a low or moderate level of energy?"	90 on activity scale (6 items)	A positive response to either of the statements: (i) I do no physical activity (ii) I do no more than 1 or 2 walks per week
Slow walking speed	Walking 4.57 m (corrected for height)	Walking 4 m (lowest sex-specific and height-specific quintile)	A positive response to the question (i) "Because of your health problem do you have difficulty walking?"	Walking 4 m (corrected for height)	A response of "Yes, limited a lot" to (SF-36–Physical Functioning) the question "Are you limited in walking one block?"
Muscle weakness	Grip strength (corrected for BMI range)	Grip strength (lowest sex-specific quintile)	Grip strength (corrected for BMI range)	Grip strength (corrected for BMI range)	A response of "Yes, limited a lot" to (SF-36–Physical Functioning) question "Are you limited in climbing one flight of stairs?"
Result	Robust 33 % Prefrail 55 % Frail 12 %	Robust 56 % Prefrail 38 % Frail 7 %	50–64 yr, +65 yr: Robust 59 %, 41 % Prefrail 37 %, 42 % Frail 4 %, 17 %	Robust 45 % Prefrail 44 % Frail 11 %	Robust 46 % Prefrail 49 % Frail 5 %

Criteria in the first column, the Cardiovascular Health Study (2001) are those proposed by Fried and colleagues

From the premise that one should proceed from simpler theories only when simplicity can be traded for greater explanatory power, it might be argued that, with the application of the criteria and threshold values from the consensus statements, it would be judicious to keep the methodologies and assumptions as simple as possible so as to test prognostic theories.

Efforts must also be made toward consistency of terminology and clarity of definitions. This is required for the terminology associated with muscle contraction, e.g., “performance,” “function,” “strength,” “quality,” “endurance,” as well as the terminology for disability and QoL concepts. A laudable plea for a common language for disablement research was made previously by Jette [40], who recommended using the language and concepts of the International Classification of Functioning, Disability and Health (ICF) framework of the World Health Organisation (WHO) [41].

## Etiology

The underlying causes of sarcopenia and frailty are multifactorial. Although the progressive loss of muscle mass with aging has been recognized for a long time, it is only with more recent techniques and longitudinal prospective studies that the age-related changes in body composition have begun to be described [42–45]. The main processes involved in the maintenance of muscle tissue and the decline toward sarcopenia are summarized in Fig. 1.

Muscle, given its usual environment of biomechanical attachment, neural inputs, and energy supply, can be

considered as having a number of positive and negative regulators that influence its maintenance and “health” [46, 47]. Thus, muscle tissue is negatively impacted when the influence of positive regulators is diminished (e.g., low vitamin D status) [48, 49] and when negative regulators are augmented (e.g., inflammatory conditions) [50]. Muscle mass is increased by physical activity and protein intake [51]. Muscle strength is increased (in all age groups) by physical activity [52].


The process of normal aging, with the changes in hormonal status (e.g., following menopause or andropause) [53, 54], with the onset of anabolic resistance [55], and with a more sedentary lifestyle, leads to loss of muscle mass and muscle strength [44, 56]. With the concerted influence of other factors, such as obesity and chronic low-grade inflammation [57], muscle loss is enhanced. This is then further exacerbated by feedback systems that are initiated in the muscle tissue. An increase in intramuscular fat at this stage is associated with an accelerated decline in muscle quality (strength per unit of mass) [58]. Another factor to be taken into consideration in older persons is the negative impact on muscle tissue of polymedication.

## Treatments for Sarcopenia and Frailty

The risk factors for sarcopenia, in addition to low physical activity and poor nutrition, include chronic inflammation and obesity and, thus, are to some extent modifiable.

The first step to be taken for a person with sarcopenia or clinical frailty is to ensure that he or she is receiving correct and sufficient nutrition [59]. An insufficient diet is

**Fig. 1** The control of muscle maintenance and the decline to sarcopenia. It is assumed that the muscle is in its usual environment of biomechanical attachment, neural input, and energy supply. *GH* growth hormone, *IGF-1* insulin-like growth factor 1, *HGF* hepatocyte growth factor, *FGF* fibroblast growth factor



quite frequent in older people [55, 60]: in a recent study of hip fracture patients admitted to hospitals in Sydney, Australia, 58 % were found to be undernourished and 55 % had a vitamin D deficiency [61]. Nutritional assessment may be made by one of a variety of questionnaires including the nutritional risk screening (NRS-2000), the simplified nutritional appetite questionnaire (SNAQ), the malnutrition universal screening tool (MUST), the mini nutritional assessment (MNA), and the SNAQ65 + (the two latter instruments have been tested in or developed for older persons [62, 63]).

It is also important that the sarcopenic/frail individual should be given minimal physical activity and if possible resistance training [52, 64, 65]. Pharmacological treatments remain, for the moment, research projects [66]. The positive effect of inhibiting angiotensin II converting enzyme is currently undergoing clinical trials, as are blockers of chronic inflammation. Trials of hormone treatments have shown either complications or no proof of efficacy, while trials of myostatin inhibitors are ongoing.

### Functional Consequences Associated with Sarcopenia and Frailty

#### Low Muscle Performance or Strength Has Prognostic Implications

In the 1990s a number of research studies in healthy older populations began observing that low muscle performance was associated with a higher risk of future disability. For example, in a key prospective study conducted by Guralnik and colleagues [67] in >70-year-old community-dwelling individuals, participants were assessed by the SPPB at baseline and then followed up by interview 4 years later. Those with lower baseline scores were associated with higher levels of disability (activity- and mobility-related) at follow-up. After adjustment for age, sex, and the presence of chronic disease, those with the lowest SPPB scores (4–6) were four times more likely to have disability at follow-up than those with the highest scores (10–12). This was later confirmed in a large-scale, multi cohort study which also noted that gait speed alone had almost the same prognostic ability as the complete SPPB [32].

Early in the following decade, the landmark study known as the Health ABC trial clearly demonstrated that the loss in muscle strength over time was greater than the loss of muscle mass (particularly the loss of fast-twitch muscle fiber). This study, which followed 1,880 older adults over 3 years, found annualized rates of decline in leg strength of 3.4 % in men and 2.6 % in women, whereas the rates of loss of leg lean mass were only about 1 % per year [68].

Subsequent mobility limitations of those enrolled in the Health ABC study were developed by 22.3 % of men and by 31.8 % of women. This loss in mobility was associated with lower muscle mass, lower muscle strength, and greater muscle tissue attenuation (a measure of fat infiltration), when analyzed using a Cox's proportional hazards model to compare the lowest quartiles to the highest in each criterion and adjusting for demographic, lifestyle, and health factors. But when all three muscle criteria were included in a single regression model, only lower muscle strength and greater muscle tissue attenuation were independently associated with incident mobility limitation ( $p < 0.05$ ) [69].

The association of body fat and physical limitation was shown at about the same period in the EPIDOS (Epidemiologie de l'Osteoporose) study, a cross-sectional investigation of older women with osteoporosis [28]. The study showed that in obese women low muscle mass was associated with an increased risk of physical limitation. But in nonobese women this association was not apparent. Thus, it would appear that low muscle strength and poor muscle quality (i.e., increasing fat infiltration) are strong indicators of functional decline, whereas low muscle mass is not.

#### Absolute Muscle Strength is a Prognostic Indicator of Functional Decline

Remarkably, it would also appear that absolute muscle strength at a point in time is a good long-term indicator of functional outcome. In a 25 year prospective cohort study in healthy men 45–68 years old, maximal handgrip strength was assessed at baseline [70]. Of the 6,089 individuals enrolled, 2,259 died over the follow-up period and 3,218 survivors (53 %) participated in the follow-up disability assessment 25 years later. Those with the lowest tertile on grip strength at study entry were associated with a very low walking speed (<0.4 m/s) (odds ratio [OR] = 2.87) and a twofold greater risk of self-care disability. These associations persisted after adjustment for multiple potential confounders including chronic conditions.

This result was recently corroborated by the Invecchiare in Chianti (InChianti) study [71], which measured grip strength, knee extension strength, and lower extremity power at baseline and mobility function (gait speed and self-reported mobility disability) in 934 adults aged  $\geq 65$  years. At the end of 3 years of follow-up, men who had low leg power (<105 W) at baseline were associated with a ninefold increase in mobility disability; low knee extension strength (<19.2 kg) and grip strength (<39.0 kg) were associated with relevant reductions in gait speed. While these associations were particularly strong in men, they showed similar trends in women.

In another cross-sectional study of 2,208 subjects (aged 55 and older), low handgrip strength and walking limitation (<1.2 m/s or difficulty walking 500 m) were correlated with increased body fat [72]. The researchers found that the prevalence of walking limitation was much higher in persons who simultaneously had a high body fat percentage and low handgrip strength (61 %) than in those with a combination of low body fat percentage and high handgrip strength (7 %).

#### Obesity Increases the Risk of Functional Decline in Frail Older Persons

As mentioned above, there appears to be a particularly high risk of functional decline when frailty is concomitant with obesity.

In the cross-sectional Women's Health and Aging studies I and II [73], 599 community-dwelling women (aged 70–79, BMI > 18.5 kg/m<sup>2</sup>) were classified for frailty status (Fried criteria). The multinomial regression model returned a significant association for obesity and frailty (OR = 3.52, 95 % confidence interval [CI] 1.34–9.13), as well as obesity and prefrailty (OR = 2.23, 95 % CI 1.29–3.84).

#### Comorbidities Associated with Sarcopenia and Frailty: Impact on Quality of Life

It seems, therefore, that sarcopenia and frailty increase the risk of physical limitation and subsequent disability; but recent research also shows that these conditions increase the risk of comorbid conditions.

In a systematic review and meta-analysis of published (prospective) studies that had assessed physical capability (using measures such as grip strength, walking speed, chair rises, and standing balance) and subsequent outcome (including fracture, cognition, cardiovascular disease, hospitalization, and institutionalization), Cooper and colleagues [74] found that those who demonstrated lower physical capability had a higher risk of negative outcomes. To be included in the analysis, all papers had to identify in their respective populations the possible confounders of the association to be studied and a description of the methods used to control for them. A few of the results in the four main categories are presented below:

**Fracture risk:** in seven out of nine study samples, researchers reported that lower grip strength was associated with a higher subsequent fracture risk; and in four out of five study samples, low walking speed was associated with a higher fracture risk.

**Cognitive function:** in three study samples that examined grip strength and cognitive function, all found that low

strength was associated with a higher subsequent risk of cognitive decline and development of Alzheimer's disease or other forms of dementia. (Also in this context, it is interesting to note that gait analysis in older people is indicative of their cognitive profile [75].)

**Cardiovascular outcomes:** in three study samples that examined grip strength and cardiovascular outcomes, one found that low strength was associated with increased risk of coronary heart disease over the subsequent 24 years, one found that low strength was associated with higher levels of fasting insulin, and the third (in women) found no association between strength and risk of stroke.

**Hospitalization:** in two out of three study samples, low walking speed was found to be associated with an increased risk of hospitalization. Additional data corroborate the association between muscle strength and hospitalization outcomes. In a small prospective cohort study of older patients ( $n = 120$ , age range 75–101 years), Kerr and colleagues [76] investigated the association between grip strength and hospitalization outcome. Using a Cox proportional hazards model, they found that higher grip strength on admission was associated with increased likelihood of discharge to usual residence. A grip strength of >18 kg for women and 31 kg for men was associated with a 25 % increase in the likelihood of return home. Others have found that low muscle strength or performance (but not muscle mass) was associated with the risk of hospitalization [77].

Low physical capability is also associated with additional comorbidities such as diabetes and risk of falling as well as increased risk of death.

- Diabetic men (previously or newly diagnosed), in the Hertfordshire cohort [78], had significantly weaker muscle strength and higher odds of impaired physical function than those without diabetes. This relationship held up also for individuals with impaired glucose tolerance and right across the normal range of glucose concentration. In women, the effect sizes were smaller and less consistent, perhaps reflecting sex differences in body composition. Subsequently, it has been shown that diabetes is associated with an accelerated loss of muscle mass and muscle strength [79, 80].
- The risk of falls is greatest in individuals with low muscle strength. The guideline published by learned geriatric societies for the prevention of falls in older persons [81] put muscle weakness as the strongest risk factor, more than a history of falls or gait or balance deficits. The older men enrolled in the MrOS study ( $n = 10,998$ ) who had a handgrip strength score >2 SD below the reference mean had a 2.4-fold higher risk of



recurrent falls (95 % CI 1.7–3.4) than older men of “normal” strength [82].

- Mortality risk, after adjustment for demographics, health behaviors, comorbidity, and cardiovascular disease risk factors, is higher in older people with low physical capability. As part of the Health ABC Study, 3,075 community-dwelling adults (aged 70–79 years, 52 % women) were asked to perform a 400 m walk test at baseline and the results were correlated with outcome after 5 years (total mortality, incident cardiovascular disease, incident mobility limitation, and mobility disability) [83]. Among those able to complete the test, each additional minute of performance time was associated with an adjusted hazard ratio (HR) of 1.29 (95 % CI 1.12–1.48) for mortality (statistically significant worsening was also seen for the other outcome measures). The crude mortality rate in the poorest quartile for the walk test was 39.9 per 1,000 person-years versus 14.2 per 1,000 in the best quartile (adjusted HR = 3.23, 95 % CI 2.11–4.94;  $p < 0.001$ ).

Similar correlations have been made between frailty and comorbidities [84]. Thus, while it seems that both of these geriatric conditions increase the risk of comorbidity, it is also evident that a number of comorbid conditions increase the risk of sarcopenia and/or frailty. In consequence, the patient enters into a vicious circle of further functional decline.

### The QoL Instruments Used in Older Populations and Relevant Disease States

#### Why Study QoL?

Health-related QoL (HR-QoL) has been defined as “a subjective measure which is evaluable over time and having a focus on the qualitative dimension of functioning,” i.e., an assessment of functional status, physical, mental, and social subjective dimensions that might provide evidence over time of the impact on the individual in terms of health status, satisfaction, and contentment in everyday life. These assessments are important for governments and health-care providers to understand the needs and preoccupations of important segments of the population, allocate resources, and define health-care reforms and initiatives accordingly. Increasingly, their concern focuses on the robustness of outcomes in relation to both the inputs and processes of health-care delivery. Since the interest is in subjective measures, the instruments are frequently referred to as patient-reported outcomes (PROs), i.e., any report of the patients’ health condition that comes directly from the patient, without interpretation of the patients’ response by a clinician or anyone else.

For complete assessment of the benefits of an intervention it is essential to provide evidence of the impact on the patient in terms of health status and HR-QoL. Such an approach is also essential in a comprehensive global assessment of older people [85] and should be taken into account in guided treatment decisions of any chronic illness.

Even in the assessment of physical functioning, the evidence suggests that self-reported and performance-based data may provide different and complementary information. This was the conclusion of a recent study in hip fracture patients [86], in which the responsiveness of self-reported measures (five-point Likert scales and Euro-QoL 5D) was compared with performance-based measures (including knee-extensor strength, the PPME [physical performance and mobility examination], chair-rise test, and maximum balance range). The researchers found that the correlations between the two approaches were only small to medium. Walking speed and chair-rise test were among the most responsive performance-based measures; the self-reported measures often indicated greater levels of disability.

There are numerous different concepts of QoL, ranging from psychological perspectives, “utilities” and the trade-offs that individuals make, to the reintegration to normal living [87]. This fact and the implicit value of having a subjective measure of welfare have resulted in a multitude of QoL instruments [88]. Two distinctive classes of instruments exist to assess HR-QoL. Generic instruments are designed to be applicable across a wide range of populations, diseases, and interventions, whereas specific instruments are relevant to particular subpopulations or illnesses. While this review is not the place to discuss all the aspects of the QoL assessments, it seems pertinent to recall a few salient points.

#### Concepts and Specificities

It is usually considered that there are three broad dimensions in the HR-QoL construct: physical/occupational function, social health/integration, and mental health/psychological state, while the non-health-related QoL includes financial and economic aspects, spiritual and political aspects, and environmental factors [87].

For any study of QoL, it is important that a conceptual framework of the QoL dimensions and subordinate domains be made [89], describing how the assessment scales relate to the studied population and to the proposed risk factor(s) of interest. This is a step that is unfortunately omitted from many research publications, hindering their comparative evaluation [90, 91]. QoL instruments should also clearly define the recall period to which patients/individuals are meant to refer. While a number of questionnaires do preface

the question blocks by “in the last week” or “in the last month,” this is not systematic and the recall periods vary considerably between instruments.

A subtle aspect of QoL studies in patients with chronic disease (or for that matter following a serious illness or intervention) is that of “response shift” or adaptation, i.e., a change in perspective of QoL accounting for actual physical condition [92]. Studies have found that older people tended to compare themselves with their peers and that the mildly frail identified themselves with those worse off and the most frail identified themselves with those doing better [85, 93]. A potential solution to this might be the use of a visual analog scale relating actual well-being with the best and worst periods in the subject’s life [94, 95], i.e., a single question which may anchor subsequent questionnaires.

The length of questionnaires is highly variable, and there is clearly a trade-off between short forms (with acceptable imprecision and high completion rates) and long forms (with greater precision and lower completion rates). Thus, there is a risk that specific QoL instruments become long and onerous to complete [96]. A contemporary approach to this response burden is computer-assisted adaptive testing, which, as an example of a questionnaire assessing disability outcomes, reduced the completion time from 20–30 minutes to 3.56 minutes without loss of measurement accuracy, precision, or reliability [96].

In pharmaco-economic studies, the utilities (preferences) for a health condition need to be established, which are then usually used to calculate quality-adjusted life years. Frequently this is done using a validated QoL questionnaire (such as the EQ-5D), but in any new area, the assumptions should be verified using another method. For example, in the study by Salkeld and colleagues [97] in hip fracture patients, this was done using the time trade-off technique. Patients (194 women aged 75–98 years) were asked to rank different health states (“full health,” “fear of falling,” “good hip fracture,” and “bad hip fracture”) and to trade off shorter periods of full health with longer periods of impaired health. The results showed that the women placed very high marginal value on their health and that 80 % would rather be dead than experience the loss of independence and the poor QoL that results for a bad hip fracture and subsequent admission to a nursing home.

### Generic QoL Instruments

Generic QoL questionnaires are widely used since they allow comparison of the burden of disease between different disease states. They carry risk, however, of being relatively insensitive to any particular pathological condition; and therefore, changes over time or treatment may be lost to background (low signal to noise).

“Broad-use” generic QoL instruments (particularly the SF-36) are popular in the study of older populations, and several comparative reviews are available [98, 99]. It has been argued, however, that the assessment of QoL in older persons should use QoL instruments that are adapted to the specificities of the age group [85, 100, 101] and differentiate between people dwelling in the community and those who are institutionalized [102]. These types of instruments have been reviewed previously [100, 103, 104].

Table 3 presents a few of the more widely reported “broad-use” generic QoL instruments and some that have been designed for older populations.

Given its widespread use, it is perhaps pertinent to discuss briefly the characteristics of the SF-36. This instrument was designed to satisfy minimum psychometric standards in a very broad range of individuals (14 years old or more) with the aim of surveying a general population for health policy objectives [105]. The eight domains (or health concepts) were selected from 40 that were included in the Medical Outcomes Study (MOS) and considered to be the most pertinent in most patients: physical functioning, physical roles, bodily pain, general health, mental health, emotional roles, social functioning, and vitality. While some of the scales of the SF-36 have been shown to have 10–20 % less precision than the long-form MOS measures they were constructed to represent, this weakness is offset by the fact that the SF-36 has a 5- to 10-fold lower response burden than the long-form questionnaire [112]. It is recognized that the SF-36 functions best as a “generic core” to compare populations across studies and that it should be supplemented with disease-specific instruments if it is to comprise a principal health outcome measure [112]. The SF-36 has been found to be a simple and effective measure of mobility-disability in epidemiological studies [113], although a substantial ceiling effect for some domains has been noted [114].

### Specific Instruments

A large number of disease-specific QoL instruments exist but none as yet specific for sarcopenia or frailty. QoL instruments do, however, exist for certain other diseases which may be of interest in defining impacted domains in sarcopenia, either because they have a relatively high prevalence in older people, such as osteoporosis and stable angina, or because they have a significant effect on physical functioning, such as chronic obstructive pulmonary disease and Parkinson’s disease.

#### *Osteoporosis*

Some of the QoL instruments that have been developed for studies in osteoporosis are presented in Table 4. Three are

**Table 3** Generic QoL instruments

Name	Number of questions	Domains (number of questions)
SF-36 MOS 36-item short form health survey [105]	36	8 Domains: general health (5), physical functioning (10), role limitation-physical (4), mental health (5), role limitation-emotional (3), social functioning (2), bodily pain (2), vitality (4)
EuroQol EQ-5D European QoL questionnaire [106]	5	5 Domains: anxiety/depression (1), mobility (1), pain/discomfort (1), self-care (1), usual activities (1)
Nottingham health profile (NHP) [107]	38	6 Domains: bodily pain (8), emotional reactions (9), energy (3), physical mobility (8), sleep (5), social isolation (5)
Instruments for older persons		
OPQOL-brief Older people's quality of life questionnaire [100]	35	8 Domains: life overall (4), health (4), social relationships and participation (5), independence, control over life and freedom (4), home and neighborhood (4), psychological and emotional well-being (4), financial circumstances (4), leisure, activities and religion (6)
CASP-19 [108]	19	4 Domains: control, autonomy, self-realization, pleasure
PGC-MAI Philadelphia geriatrics center multilevel assessment instrument [109]	147 (+ mid-length [68] + short [24])	6 Domains: ADL (16), cognition (10), perceived environment (25), personal adjustment (12), physical health (49), social interaction (17), time use (18)
PWB Perceived well-being scale [109]	14	2 Domains: psychological well-being (6), physical well-being (8)
ACSA Anamnestic comparative self-assessment scale [94]	14	1 Domain: subjective well-being—the ACSA asks the patient to remember the best and worst periods of his or her life experience (assigned +5 and -5, respectively), then to rate current life satisfaction (over period).
LEIPAD [110]	49	7 Domains: cognitive function (5), depression/anxiety (4), life satisfaction (6), physical function (5), self-care (6), sexual function (2), social function (3) & other moderator scales (18)
WHOQoL-Old [111]	24	6 Domains: sensory abilities (4); autonomy (4); past, present, and future activities (4); social participation (4); death and dying (4); intimacy (4)

*ADL* activities of daily living, *IADL* instrumental activities of daily living

self-administered questionnaires, and three are given by an interviewer. The number of domains assessed varies from two to seven and the number of questions, from 23 to 84.

### Heart Disease

The impact of chronic cardiovascular disease on QoL has been investigated in numerous studies, and several specific instruments are available [88]. Studies of stable angina are of potential interest since the patients are frequently older, community-dwelling women. Of note are the HeartQoL questionnaire and the Seattle Angina questionnaire. Patients with heart failure are usually more severe, and these specific instruments (e.g., the Minnesota living with heart failure questionnaire and the Kansas City cardiomyopathy questionnaire) are of less interest.

### Muscle Disease

The individualised neuromuscular QoL instrument (INQOL) is a 45-item questionnaire designed for patients

with muscle diseases that examines the impact of symptoms (weakness, myotonia, pain, and fatigue), the effects they have on aspects of daily life, and the positive and negative effects of treatment [121].

### Chronic obstructive Pulmonary Disease

The impact of this disease on QoL has been examined in several studies, and a pertinent review is that by Gimeno-Santos and colleagues [90].

### Studies of QoL Assessment in Sarcopenic or Frail Populations

Studies that assessed QoL in populations of older community-dwelling individuals with a diagnosis of either sarcopenia or frailty are presented in Table 5. Of the eight studies identified, five used the SF-36; the other instruments were the OPQOL, the WHOQoL-Bref, and the quality of life systemic inventory questionnaire. In three of the studies using the SF-36 (in frail patients), the mean

**Table 4** QoL instruments for osteoporosis

Name	Administration	Number of questions	Domains (questions)
Qualeffo-41 [115]	Self-administration	41, short version: 31	7 Domains: pain (5), physical function-ADL (4), physical function-IADL (5), physical function-mobility (8), social function (7), general Health perception (3), mental function (9)
QUALIOST (questionnaire QoL in osteoporosis) [116]	Self-administration	23	2 domains: physical function, emotional status
OPAQ (osteoporosis assessment questionnaire) [117]	Self-administration	Version 1: 84 Version 2: 60 Version 3: 34	4 Domains: physical function, emotional status, symptoms, social interaction
OQLQ (osteoporosis QoL questionnaire) [118]	Interviewer	30, short version:10	3 Domains: physical function, emotional function, ADL
OFDQ (Osteoporosis Functional Disability Questionnaire) [119]	Interviewer	69	6 Domains: general health, back pain, confidence, ADL, socialization, depression
OPTQoL (osteoporosis-targeted QoL questionnaire) [120]	Interviewer	33	3 Domains: physical activity, adaptations, fears

*ADL* activities of daily living, *IADL* instrumental activities of daily living

physical and mental summary values were presented; and these show notable heterogeneity. Also apparent from these three studies is that the SDs for the means in the robust, prefrail, and frail groups equal or exceed the differences between the groups. In this respect, the OPQOL scores appear to show a more satisfactory result.

In the cross-sectional Hertfordshire cohort study [114], in nearly 3,000 community-dwelling men and women aged 59–73 years, the relationships between grip strength and HR-QoL using the SF-36 were investigated. The results showed (using simple unadjusted analyses) that low grip strength (in both men and women) was associated with increased prevalence of having poor scores for all of the domains of the SF-36 instrument. With adjustment for age, height, weight, walking speed, social class, smoking, alcohol consumption, and known comorbidity, lower grip strength remained associated with a low physical functioning score and a low general health score. These relationships were not explained by falls history. Thus, even after adjusting for muscle performance (walking speed), low muscle strength (handgrip) was associated with low HR-QoL

#### Frailty is Associated with Poor QoL

Frail and prefrail individuals have lower QoL scores compared to age- and comorbidity-matched nonfrail individuals. One relevant study in this context is the hispanic established populations epidemiologic studies of the elderly (Hispanic-EPESSE), which enrolled 1,008 older adults living in the community [122]. The results showed, after adjusting for sociodemographic and health-related covariables, that being prefrail or frail was significantly

associated ( $p < 0.001$ ) with lower scores on all physical and cognitive HR-QoL scales than being nonfrail. Furthermore, in a longitudinal study of 484 community-dwelling persons 75 years and older frailty status was assessed at baseline (Tilburg Frailty Indicator) and QoL was assessed after 1 and 2 years (WHOQoL-BREF) [126]. The results revealed very large associations between frailty status and poor QoL.

In older, frail nursing home residents it has been shown that muscle fatigability (assessed by sustained grip strength) was related to both self-perceived fatigue and QoL (WHOQOL, Mobility-Tiredness scale, physical domain score of SF-36) [128]. Since fatigue is often considered a key element in frailty, its estimation both objectively and subjectively might help to distinguish the muscular (related to sarcopenia) and mental components affecting QoL in these patients.

#### Conclusions on QoL Research in Older Populations

What emerges from this research in older populations (and mostly from generic QoL instruments or structured interviews) is that physical functioning plays an extremely important role in QoL. The striking thing about this conclusion is the similarity to the drivers of QoL in patients with chronic diseases [99].

The main drivers of QoL in older adults are, therefore, energy, freedom from pain, ability to do activities of daily living, and ability to move around [97, 101]. Those who regularly do at least 1 h per week of moderately intense physical activity had higher HR-QoL measures (on SF-36) than those who do not [129]. They have a strong need, the

**Table 5** Studies of community-dwelling populations having a diagnosis of sarcopenia or frailty and QoL assessment

Study	Population	Diagnosis of sarcopenia/frailty	QoL	Results
Sayer et al. [114] England	<i>n</i> = 2,987; age 59–73 years, mean age = 66.6 years; 47 % of cohort were women	Sarcopenia: grip strength (mean 44.0 ± 7.5 kg for men and 26.5 ± 5.8 kg for women)	SF-36	Decreased grip strength correlated with: Men Poor PH and GH Women Poor PH, GH, RP, VT, and BP
Masel et al. [122] USA (Hispanic population)	<i>n</i> = 1,008; age 74 years and older, mean age = 82.3 ± 4.3 years; 63 % women; 40 % overweight, 26 % obese	Frailty (fried criteria)	SF-36	Pop QoL physical QoL mental (subscores) Robust 26 % 44 ± 10 58 ± 6 Prefrail 54 % 36 ± 12 54 ± 11 Frail 20 % 29 ± 10 47 ± 13
Bilotta et al. [93] Italy	<i>n</i> = 239; mean age = 81.5 ± 6.3 years; 67 % women; 4.3 chronic diseases; 5.4 drugs/day; 26 % had depression/dementia	Frailty using the 3 criteria from study of osteoporotic fractures (weight loss, exhaustion, 5 times chair rise exercise)	OPQOL	Pop OPQOL total score Robust 30 % 126 ± 13 Prefrail 37 % 116 ± 14 Frail 33 % 107 ± 13
Lin et al. [123] Taiwan	<i>n</i> = 933; 38 % aged 65–70 years; 25 % aged 71–75 years, 37 % aged > 75 years; 48 % women	Frailty (fried criteria)	SF-36	Pop QoL physical QoL mental (subscores) Robust 47 % 50 (SE 0.5) 56 (SE 0.6) Prefrail 44 % 48 (SE 0.5) 54 (SE 0.6) Frail 10 % 43 (SE 0.8) 53 (SE 0.9)
Chang et al. [124] Taiwan	<i>n</i> = 374; mean age = 74.6 ± 6.3 years; 53 % women; 16 % with fall in previous year; number of comorbidities = 1.4 ± 1.2;	Frailty (fried criteria) and using TGUG for slowness criterion (lowest 20 %)	SF-36	Pop QoL physical QoL mental (subscores) Robust 31 % 49 ± 8 57 ± 8 Prefrail 63 % 48 ± 8 52 ± 9 Frail 6 % 40 ± 8 43 ± 12
Kull et al. [125] Estonia	<i>n</i> = 227; aged 40–70 years, mean age = 55 years; 53 % women	Sarcopenia: handgrip strength <6.5 kg/cm <sup>2</sup> F, <24.4 kg/cm <sup>2</sup> M; or ALAM using DXA < 4.87 kg/m <sup>2</sup> F, < 6.60 kg/m <sup>2</sup> M (BMD also measured)	SF-36	Pop QoL Physical QoL Mental (sub) Normal 53 % 50 48 Sarcopenic 14 % na na Osteopenic 39 % 50 49 “Sarco-osteopenic” 7 % 47 42
Gobbens et al. [126] Netherlands	<i>n</i> = 484; aged 75 years and older; <i>n</i> = 336 at 1 year follow-up; <i>n</i> = 266 at 2-year follow-up	Frailty assessed according to the tilburg frailty indicator at baseline	WHOQOL-BREF	Medium to very large associations of frailty with adverse outcomes and poor QoL 1 or 2 years later

Table 5 continued

	Population	Diagnosis of sarcopenia/frailty	QoL	Results
Langlois et al. [127]	Canada $n = 83$ (39 frail + 44 nonfrail)	Frailty assessed using a geriatric examination and scored using the modified physical performance test	QLSI	Frail elders reported poor self-perception of physical capacity, cognition, affectivity, housekeeping efficacy, and physical health

47 All studies were of community-dwelling individuals; all studies except Gobbens et al. [126] were cross-sectional; unless stated, patients were at least 65 years old for inclusion  
 ALM appendicular lean mass, BMD bone mineral density, BP bodily pain, DXA dual-energy X-ray absorptiometry, GH general health, na not available, PH physical health, Pop population, QLSI Quality of Life Systemic Inventory Questionnaire, RP role physical, VT vitality

“need to stay independent” and maintain self-efficacy; any perceived threat to these ideals has a strong negative impact on QoL [85, 130].

Yet these drivers (domains) remain difficult to quantify:

- The lack of energy (anergia) experienced by some older adults is a complex phenomenon that is often associated with underlying chronic conditions, such as inflammation, undernutrition, pain, masked depression, and cognitive and functional decline [93]. The concept of “mental energy” in itself is a three-dimensional construct consisting of mood (transient feelings about the presence of fatigue or energy), motivation (determination and enthusiasm), and cognition (sustained attention and vigilance) [131].
- The physical activity domain is challenging since there is a huge number of possible subdomains and items. In a review of 104 patient-reported physical activity questionnaires for chronic diseases and older populations, Williams and colleagues [99] identified 182 physical activity (sub) domains with 1,965 associated items. They concluded, as others have done, that it is crucial to construct a conceptual framework for the areas and boundaries of physical activity early on in such a project.

While the QoL instruments usually refer to the dimension of “physical function,” it should be considered that its reciprocal is “disability” [132]—it is thus a question of perspective. Some clinical specialities, for example, rheumatology and gerontology, have a historical preference for the term “disability” over “physical function.” But if one should adopt the language of the ICF, then one should use “disability” with the concept of an impairment of functioning with respect to generally accepted population standards [41].

It is clear that any new instrument would need to be thoroughly validated in terms of its reliability and sensitivity to change. This aspect of QoL instrument development has advanced significantly in recent years with the publication of the COSMIN guidelines, which provide consensus-based standards for the evaluation and development of health-related PROs [133, 134].

As part of the FDA roadmap initiative, PROMIS (patient-reported outcomes measurement information system) sets out to provide clinical researchers with a bank of validated QoL modules that can be assembled for computerized scoring [135]. It has defined three main components (dimensions): physical health, mental health and social health, with seven subcomponents and 16 domains (e.g., pain, fatigue, physical function, negative/positive affect, social isolation, ability to participate in social activities). In early testing within the field of rheumatology, these modules appear to be effective in assessing self-reported physical functioning [132, 136].

There are frequent calls from members of the research community for an approach that uses utility weighting. The value of a measure that can be integrated over time to obtain an overall figure for disability (or disutility) is well known. Possibly a time trade-off study such as that used by Salkeld and colleagues [97] would be applicable in this population. This approach will be helpful to evaluate the burden of the disease.

In any construct that purports to assess QoL in sarcopenia it will be important to try to understand the effect size of disability on overall QoL. Sarcopenia may only lead to poor QoL in a context of disability, and this will be vital to dissect. Frailty is always associated with disability and, thus, carries an inherently greater risk of poor QoL.

An ideal QoL construct in sarcopenia would assess the physical aspects of the musculoskeletal domain and give an even-handed balance to the other factors affecting QoL. It is anticipated that, as a patient-reported measure, it would complement the objective assessments of physical performance [137]. It would include the functionality of articulations and the impact of bone health as well as an assessment of pain, fatigue, and the emotional aspects and other non-health-related dimensions of the conditions. It should also take into account any change in weight and perhaps certain behavioral changes to help explain longitudinal differences. A comprehensive construct, coupled with multivariate analysis models, would provide the most useful outcome trajectories.

### Conclusions on Goals and Challenges of QoL Assessment in Frailty and Sarcopenia

With the publication of three, fairly similar consensus definitions for sarcopenia, important progress has been

made; and it is expected that future research will build on this new foundation. It may be hoped that a consensus definition for frailty might soon also see the light of day, for it is clear that medical research and practice advances by the definition of formal criteria that define clinical syndromes. Examples of this in the past include Alzheimer's disease and osteoporosis [138], recognized pathological conditions that were once just syndromes.


While the two conditions, sarcopenia and frailty, are closely related, it may be seen that sarcopenia is a key component of frailty. This is shown schematically in Fig. 2. Both conditions may be considered as being geriatric syndromes with multifactorial causes, both increasing the risk of serious disability with a consequent and strong impact on health-care costs. It is therefore critical to halt or slow down this progression. Proactive steps should therefore be taken early following diagnosis.

Efforts must now be made so that the consensus definitions are widely recognized and refined accordingly. The application of terms, measurement techniques, and cutoffs must be used consistently.

An important question will be, is it necessary to develop from scratch specific QoL instruments for sarcopenia and frailty? Or are there available instruments that can be adapted? A variety of PRO instruments have been developed for older populations as well as some relevant disease-specific instruments, so it may be that some part could be adapted. Also to be considered are the growing number of modules available in the PROMIS program. The SF-36 should still serve as a generic core, but its limitations are evident.

It can be hoped that health-care providers and regulatory agencies will recognize that these age-related conditions invoke high personal and social costs and are suitable

Fig. 2 The domains of frailty



targets for intervention [139]. In this regard, the European Medicines Agency with its Geriatric Medicines Strategy has taken initial steps for fostering the development of geriatric medicines and incorporating geriatric aspects into the assessment at authorization and postmarketing surveillance of approved drugs [140]. The European commission, via the innovation partnership on active and healthy ageing (EIP on AHA), has put a target of adding two healthy life years to citizens by 2020 [141]. Improvements in geriatric medicine will help to make this goal achievable.

**Acknowledgement** The authors thank Jeremy Grierson, PhD, for his assistance in preparing the draft of the manuscript from the presentations and discussions of the working group participants.

## References

- Rosenberg IH (2011) Sarcopenia: origins and clinical relevance. *Clin Geriatr Med* 27:337–339
- Malafarina V, Uriz-Otano F, Iniesta R, Gil-Guerrero L (2012) Sarcopenia in the elderly: diagnosis, physiopathology and treatment. *Maturitas* 71:109–114
- Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M (2010) Sarcopenia: European consensus on definition and diagnosis—Report of the European working group on Sarcopenia in older people. *Age Ageing* 39:412–423
- Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, Boirie Y, Bosaes I, Cederholm T, Costelli P, Fearon KC, Laviano A, Maggio M, Rossi FF, Schneider SM, Schols A, Sieber CC (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by special interest groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics.”. *Clin Nutr* 29:154–159
- Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G, Andrieu S, Bauer J, Breuille D, Cederholm T, Chandler J, de Meynard C, Donini L, Harris T, Kannt A, Keime GF, Onder G, Papanicolaou D, Rolland Y, Rooks D, Sieber C, Souhami E, Verlaan S, Zamboni M (2011) Sarcopenia: an undiagnosed condition in older adults—Current consensus definition: prevalence, etiology, and consequences. international working group on Sarcopenia. *J Am Med Dir Assoc* 12:249–256
- Abellan van Kan G, Rolland Y, Bergman H, Morley JE, Kritchevsky SB, Vellas B (2008) The I.A.N.A task force on frailty assessment of older people in clinical practice. *J Nutr Health Aging* 12:29–37
- Gielen E, Verschuere S, O’Neill TW, Pye SR, O’Connell MD, Lee DM, Ravindrarajah R, Claessens F, Laurent M, Milisen K, Tournoy J, Dejaeger M, Wu FC, Vanderschueren D, Boonen S (2012) Musculoskeletal frailty: a geriatric syndrome at the core of fracture occurrence in older age. *Calcif Tissue Int* 91:161–177
- Cooper C, Dere W, Evans W, Kanis JA, Rizzoli R, Sayer AA, Sieber CC, Kaufman JM, Abellan van Kan G, Boonen S, Adachi J, Mitlak B, Tsouderos Y, Rolland Y, Reginster JY (2012) Frailty and sarcopenia: definitions and outcome parameters. *Osteoporos Int* 23:1839–1848
- Boyd CM, Xue QL, Simpson CF, Guralnik JM, Fried LP (2005) Frailty, hospitalization, and progression of disability in a cohort of disabled older women. *Am J Med* 118:1225–1231
- Landi F, Liperoti R, Russo A, Giovannini S, Tosato M, Capoluongo E, Bernabei R, Onder G (2012) Sarcopenia as a risk factor for falls in elderly individuals: results from the iLSIRENTE study. *Clin Nutr* 31:652–658
- Landi F, Cruz-Jentoft AJ, Liperoti R, Russo A, Giovannini S, Tosato M, Capoluongo E, Bernabei R, Onder G (2013) Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from the iLSIRENTE study. *Age Ageing* 42:203–209
- Pertermans J (2012) Pathological ageing: a myth or reality [in French]? *Rev Med Liege* 67:341–348
- Clark BC, Manini TM (2008) Sarcopenia  $\neq$  dynapenia. *J Gerontol A Biol Sci Med Sci* 63:829–834
- Bauer JM, Sieber CC (2008) Sarcopenia and frailty: a clinician’s controversial point of view. *Exp Gerontol* 43:674–678
- Fried LP, Xue QL, Cappola AR, Ferrucci L, Chaves P, Varadhan R, Guralnik JM, Leng SX, Semba RD, Walston JD, Blaum CS, Bandeen-Roche K (2009) Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. *J Gerontol A Biol Sci Med Sci* 64:1049–1057
- Rodriguez-Manas L, Feart C, Mann G, Vina J, Chatterji S, Chodzko-Zajko W, Gonzalez-Colaco HM, Bergman H, Carcaillon L, Nicholson C, Scuteri A, Sinclair A, Pelaez M, Van der Cammen T, Beland F, Bickenbach J, Delamarche P, Ferrucci L, Fried LP, Gutierrez-Robledo LM, Rockwood K, Rodriguez AF, Serviddio G, Vega E (2013) Searching for an operational definition of frailty: a delphi method based consensus statement: the frailty operative definition-consensus conference project. *J Gerontol A Biol Sci Med Sci* 68:62–67
- Rockwood K, Stadnyk K, MacKnight C, McDowell I, Hebert R, Hogan DB (1999) A brief clinical instrument to classify frailty in elderly people. *Lancet* 353:205–206
- Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA (2001) Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 56:M146–M156
- Romero-Ortuno R (2013) The frailty instrument for primary care of the survey of health, ageing and retirement in Europe predicts mortality similarly to a frailty index based on comprehensive geriatric assessment. *Geriatr Gerontol Int* 13:497–504
- Hogan DB, MacKnight C, Bergman H (2003) Models, definitions, and criteria of frailty. *Aging Clin Exp Res* 15:1–29
- Markle-Reid M, Browne G (2003) Conceptualizations of frailty in relation to older adults. *J Adv Nurs* 44:58–68
- Puts MT, Lips P, Deeg DJ (2005) Sex differences in the risk of frailty for mortality independent of disability and chronic diseases. *J Am Geriatr Soc* 53:40–47
- Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L (2008) Sarcopenic obesity: definition, cause and consequences. *Curr Opin Clin Nutr Metab Care* 11:693–700
- Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi FF, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD (2008) Cachexia: a new definition. *Clin Nutr* 27:793–799
- Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD (1998) Epidemiology of sarcopenia among the elderly in New Mexico. *Am J Epidemiol* 147:755–763
- Newman AB, Kupelian V, Visser M, Simonsick E, Goodpaster B, Nevitt M, Kritchevsky SB, Tyllavsky FA, Rubin SM, Harris TB (2003) Sarcopenia: alternative definitions and associations with lower extremity function. *J Am Geriatr Soc* 51:1602–1609
- Baumgartner RN, Wayne SJ, Waters DL, Janssen I, Gallagher D, Morley JE (2004) Sarcopenic obesity predicts instrumental



- activities of daily living disability in the elderly. *Obes Res* 12:1995–2004
28. Rolland Y, Lauwers-Cances V, Cristini C, Abellan van Kan G, Janssen I, Morley JE, Vellas B (2009) Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: the EPIDOS (EPIDemiologie de l'OSteoporose) Study. *Am J Clin Nutr* 89:1895–1900
  29. Asher L, Aresu M, Falaschetti E, Mindell J (2012) Most older pedestrians are unable to cross the road in time: a cross-sectional study. *Age Ageing* 41:690–694
  30. Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A, Corsi AM, Rantanen T, Guralnik JM, Ferrucci L (2003) Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. *J Appl Physiol* 95:1851–1860
  31. Cesari M, Kritchevsky SB, Penninx BW, Nicklas BJ, Simonsick EM, Newman AB, Tyllavsky FA, Brach JS, Satterfield S, Bauer DC, Visser M, Rubin SM, Harris TB, Pahor M (2005) Prognostic value of usual gait speed in well-functioning older people—results from the health, aging and body composition study. *J Am Geriatr Soc* 53:1675–1680
  32. Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV, Studenski S, Berkman LF, Wallace RB (2000) Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. *J Gerontol A Biol Sci Med Sci* 55:M221–M231
  33. van Iersel MB, Rikkert MG (2006) Frailty criteria give heterogeneous results when applied in clinical practice. *J Am Geriatr Soc* 54:728–729
  34. Ble A, Cherubini A, Volpato S, Bartali B, Walston JD, Windham BG, Bandinelli S, Lauretani F, Guralnik JM, Ferrucci L (2006) Lower plasma vitamin E levels are associated with the frailty syndrome: the InChianti study. *J Gerontol A Biol Sci Med Sci* 61:278–283
  35. Romero-Ortuno R, Walsh CD, Lawlor BA, Kenny RA (2010) A frailty instrument for primary care: findings from the survey of health, ageing and retirement in Europe (SHARE). *BMC Geriatr* 10:57
  36. Chang SS, Weiss CO, Xue QL, Fried LP (2010) Patterns of comorbid inflammatory diseases in frail older women: the women's health and aging studies I and II. *J Gerontol A Biol Sci Med Sci* 65:407–413
  37. Rolland Y, Abellan van Kan G, Gillette-Guyonnet S, Roux C, Boonen S, Vellas B (2011) Strontium ranelate and risk of vertebral fractures in frail osteoporotic women. *Bone* 48:332–338
  38. Mijnders DM, Meijers JM, Halfens RJ, Ter BS, Luiking YC, Verlaan S, Schoberer D, Cruz Jentoft AJ, van Loon LJ, Schols JM (2012) Validity and reliability of tools to measure muscle mass, strength, and physical performance in community-dwelling older people: a systematic review. *J Am Med Dir Assoc* 14:170–178
  39. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA (2011) A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. *Age Ageing* 40:423–429
  40. Jette AM (2009) Toward a common language of disablement. *J Gerontol A Biol Sci Med Sci* 64:1165–1168
  41. World Health Organisation (2002) Towards a common language for functioning, disability and health—the international classification of functioning, disability and health. <http://www.who.int/classifications/icf/training/icfbeginnersguide.pdf>. Cited 7 Mar 2013
  42. Delmonico MJ, Harris TB, Visser M, Park SW, Conroy MB, Velasquez-Mieryer P, Boudreau R, Manini TM, Nevitt M, Newman AB, Goodpaster BH (2009) Longitudinal study of muscle strength, quality, and adipose tissue infiltration. *Am J Clin Nutr* 90:1579–1585
  43. Fantin F, Di Francesco V, Fontana G, Zivelonghi A, Bissoli L, Zoico E, Rossi A, Micciolo R, Bosello O, Zamboni M (2007) Longitudinal body composition changes in old men and women: interrelationships with worsening disability. *J Gerontol A Biol Sci Med Sci* 62:1375–1381
  44. Frontera WR, Reid KF, Phillips EM, Krivickas LS, Hughes VA, Roubenoff R, Fielding RA (2008) Muscle fiber size and function in elderly humans: a longitudinal study. *J Appl Physiol* 105:637–642
  45. Song MY, Ruts E, Kim J, Janumala I, Heymsfield S, Gallagher D (2004) Sarcopenia and increased adipose tissue infiltration of muscle in elderly African American women. *Am J Clin Nutr* 79:874–880
  46. Hamrick MW (2011) A role for myokines in muscle-bone interactions. *Exerc Sport Sci Rev* 39:43–47
  47. Pedersen BK, Febbraio MA (2012) Muscles, exercise and obesity: skeletal muscle as a secretory organ. *Nat Rev Endocrinol* 8:457–465
  48. Bischoff-Ferrari HA (2012) Relevance of vitamin D in muscle health. *Rev Endocr Metab Disord* 13:71–77
  49. Body JJ, Bergmann P, Boonen S, Devogelaer JP, Gielen E, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY (2012) Extraskelletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. *Osteoporos Int* 23(Suppl 1):S1–S23
  50. Sakuma K, Yamaguchi A (2012) Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. *J Cachexia Sarcopenia Muscle* 3:77–94
  51. Genaro PS, Martini LA (2010) Effect of protein intake on bone and muscle mass in the elderly. *Nutr Rev* 68:616–623
  52. Waters DL, Baumgartner RN, Garry PJ, Vellas B (2010) Advantages of dietary, exercise-related, and therapeutic interventions to prevent and treat sarcopenia in adult patients: an update. *Clin Interv Aging* 5:259–270
  53. Carcaillon L, Garcia-Garcia FJ, Tresguerres JA, Gutierrez AG, Kireev R, Rodriguez-Manas L (2012) Higher levels of endogenous estradiol are associated with frailty in postmenopausal women from the toledo study for healthy aging. *J Clin Endocrinol Metab* 97:2898–2906
  54. Carcaillon L, Blanco C, Alonso-Bouzon C, Alfaro-Acha A, Garcia-Garcia FJ, Rodriguez-Manas L (2012) Sex differences in the association between serum levels of testosterone and frailty in an elderly population: the toledo study for healthy aging. *PLoS One* 7:e32401
  55. Breen L, Phillips SM (2011) Skeletal muscle protein metabolism in the elderly: interventions to counteract the “anabolic resistance” of ageing. *Nutr Metab (Lond)* 8:68
  56. Faulkner JA, Larkin LM, Claflin DR, Brooks SV (2007) Age-related changes in the structure and function of skeletal muscles. *Clin Exp Pharmacol Physiol* 34:1091–1096
  57. Beyer I, Mets T, Bautmans I (2012) Chronic low-grade inflammation and age-related sarcopenia. *Curr Opin Clin Nutr Metab Care* 15:12–22
  58. Goodpaster BH, Carlson CL, Visser M, Kelley DE, Scherzinger A, Harris TB, Stamm E, Newman AB (2001) Attenuation of skeletal muscle and strength in the elderly: the health ABC study. *J Appl Physiol* 90:2157–2165
  59. Mithal A, Bonjour JP, Boonen S, Burckhardt P, Degens H, El Hajj FG, Josse R, Lips P, Morales TJ, Rizzoli R, Yoshimura N, Wahl DA, Cooper C, Dawson-Hughes B (2013) Impact of nutrition on muscle mass, strength, and performance in older adults. *Osteoporos Int* 24:1555–1566
  60. Morley JE (2012) Undernutrition in older adults. *Fam Pract* 29:i89

61. Fiatarone Singh MA, Singh NA, Hansen RD, Finnegan TP, Allen BJ, Diamond TH, Diwan AD, Lloyd BD, Williamson DA, Smith EU, Grady JN, Stavrinou TM, Thompson MW (2009) Methodology and baseline characteristics for the Sarcopenia and hip fracture study: a 5 year prospective study. *J Gerontol A Biol Sci Med Sci* 64:568–574
62. Cuervo M, Garcia A, Ansorena D, Sanchez-Villegas A, Martinez-Gonzalez M, Astiasaran I, Martinez J (2009) Nutritional assessment interpretation on 22,007 Spanish community-dwelling elders through the mini nutritional assessment test. *Public Health Nutr* 12:82–90
63. Wijnhoven HA, Schilp J, van Bokhorst-de van der Schueren MA, de Vet HC, Kruizenga HM, Deeg DJ, Ferrucci L, Visser M (2012) Development and validation of criteria for determining undernutrition in community-dwelling older men and women: the short nutritional assessment questionnaire 65+. *Clin Nutr* 31:351–358
64. Kim JS, Wilson JM, Lee SR (2010) Dietary implications on mechanisms of sarcopenia: roles of protein, amino acids and antioxidants. *J Nutr Biochem* 21:1–13
65. Liu CK, Fielding RA (2011) Exercise as an intervention for frailty. *Clin Geriatr Med* 27:101–110
66. Rolland Y, Onder G, Morley JE, Gillette-Guyonnet S, Abellan van Kan G, Vellas B (2011) Current and future pharmacologic treatment of sarcopenia. *Clin Geriatr Med* 27:423–447
67. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB (1995) Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. *N Engl J Med* 332:556–561
68. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, Simonsick EM, Tylavsky FA, Visser M, Newman AB (2006) The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. *J Gerontol A Biol Sci Med Sci* 61:1059–1064
69. Visser M, Goodpaster BH, Kritchevsky SB, Newman AB, Nevitt M, Rubin SM, Simonsick EM, Harris TB (2005) Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. *J Gerontol A Biol Sci Med Sci* 60:324–333
70. Rantanen T, Guralnik JM, Foley D, Masaki K, Leveille S, Curb JD, White L (1999) Midlife hand grip strength as a predictor of old age disability. *JAMA* 281:558–560
71. Hicks GE, Shardell M, Alley DE, Miller RR, Bandinelli S, Guralnik J, Lauretani F, Simonsick EM, Ferrucci L (2012) Absolute strength and loss of strength as predictors of mobility decline in older adults: the InChianti study. *J Gerontol A Biol Sci Med Sci* 67:66–73
72. Stenholm S, Rantanen T, Heliovaara M, Koskinen S (2008) The mediating role of C-reactive protein and handgrip strength between obesity and walking limitation. *J Am Geriatr Soc* 56:462–469
73. Blaum CS, Xue QL, Michelson E, Semba RD, Fried LP (2005) The association between obesity and the frailty syndrome in older women: the women's health and aging studies. *J Am Geriatr Soc* 53:927–934
74. Cooper R, Kuh D, Cooper C, Gale CR, Lawlor DA, Matthews F, Hardy R (2011) Objective measures of physical capability and subsequent health: a systematic review. *Age Ageing* 40:14–23
75. Gillain S, Warzee E, Lekeu F, Wojtasik V, Maquet D, Croisier JL, Salmon E, Petermans J (2009) The value of instrumental gait analysis in elderly healthy, MCI or Alzheimer's disease subjects and a comparison with other clinical tests used in single and dual-task conditions. *Ann Phys Rehabil Med* 52:453–474
76. Kerr A, Syddall HE, Cooper C, Turner GF, Briggs RS, Sayer AA (2006) Does admission grip strength predict length of stay in hospitalised older patients? *Age Ageing* 35:82–84
77. Cawthon PM, Fox KM, Gandra SR, Delmonico MJ, Chiou CF, Anthony MS, Sewall A, Goodpaster B, Satterfield S, Cummings SR, Harris TB (2009) Do muscle mass, muscle density, strength, and physical function similarly influence risk of hospitalization in older adults? *J Am Geriatr Soc* 57:1411–1419
78. Sayer AA, Dennison EM, Syddall HE, Gilbody HJ, Phillips DI, Cooper C (2005) Type 2 diabetes, muscle strength, and impaired physical function: the tip of the iceberg? *Diabetes Care* 28:2541–2542
79. Park SW, Goodpaster BH, Strotmeyer ES, Kuller LH, Broudeau R, Kammerer C, de Rekeneire N, Harris TB, Schwartz AV, Tylavsky FA, Cho YW, Newman AB (2007) Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. *Diabetes Care* 30:1507–1512
80. Park SW, Goodpaster BH, Lee JS, Kuller LH, Boudreau R, de Rekeneire N, Harris TB, Kritchevsky S, Tylavsky FA, Nevitt M, Cho YW, Newman AB (2009) Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. *Diabetes Care* 32:1993–1997
81. AGS/BGS/AAOS (2001) Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. *J Am Geriatr Soc* 49:664–672
82. Karlsson MK, Ribom E, Nilsson JA, Ljunggren O, Ohlsson C, Mellstrom D, Lorentzon M, Mallmin H, Stefanick M, Lapidus J, Leung PC, Kwok A, Barrett-Connor E, Orwoll E, Rosengren BE (2012) Inferior physical performance tests in 10,998 men in the MrOS study is associated with recurrent falls. *Age Ageing* 41:740–746
83. Newman AB, Simonsick EM, Naydeck BL, Boudreau RM, Kritchevsky SB, Nevitt MC, Pahor M, Satterfield S, Brach JS, Studenski SA, Harris TB (2006) Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. *JAMA* 295:2018–2026
84. Zaslavsky O, Cochrane BB, Thompson HJ, Woods NF, Herting JR, Lacroix A (2013) Frailty: a review of the first decade of research. *Biol Res Nurs*
85. Puts MT, Shekary N, Widdershoven G, Heldens J, Lips P, Deeg DJ (2007) What does quality of life mean to older frail and non-frail community-dwelling adults in the Netherlands? *Qual Life Res* 16:263–277
86. Farag I, Sherrington C, Kamper SJ, Ferreira M, Moseley AM, Lord SR, Cameron ID (2012) Measures of physical functioning after hip fracture: construct validity and responsiveness of performance-based and self-reported measures. *Age Ageing* 41:659–664
87. Spilker B (1996) Developing guidelines for pharmaco-economic studies. In: Spilker B (ed) *Quality of life and pharmacoeconomics in clinical trials*, 2nd edn. Lippincott-Raven, Philadelphia, pp 1123–1130
88. Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R (2002) Quality of life measurement: bibliographic study of patient assessed health outcome measures. *BMJ* 324:1417
89. US FDA (2009) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf>
90. Gimeno-Santos E, Frei A, Dobbels F, Rudell K, Puhon MA, Garcia-Aymerich J (2011) Validity of instruments to measure physical activity may be questionable due to a lack of conceptual frameworks: a systematic review. *Health Qual Life Outcomes* 9:86
91. Medical Outcomes Trust (2002) Assessing health status and quality-of-life instruments: attributes and review criteria. *Qual Life Res* 11:193–205

92. Ubel PA, Peeters Y, Smith D (2010) Abandoning the language of “response shift”: a plea for conceptual clarity in distinguishing scale recalibration from true changes in quality of life. *Qual Life Res* 19:465–471
93. Bilotta C, Bowling A, Case A, Nicolini P, Mauri S, Castelli M, Vergani C (2010) Dimensions and correlates of quality of life according to frailty status: a cross-sectional study on community-dwelling older adults referred to an outpatient geriatric service in Italy. *Health Qual Life Outcomes* 8:56
94. Bernheim JL (1999) How to get serious answers to the serious question “How have you been?”: subjective quality of life (QOL) as an individual experiential emergent construct. *Bioethics* 13:272–287
95. Bernheim JL, Theuns P, Mazaheri M, Hofmans J, Fliege H, Rose M (2006) The potential of anamnestic comparative self-assessment (ACSA) to reduce bias in the measurement of subjective well-being. *J Happiness Studies* 7:227–250
96. McDonough CM, Tian F, Ni P, Kopits IM, Moed R, Pardasany PK, Jette AM (2012) Development of the computer-adaptive version of the late-life function and disability instrument. *J Gerontol A Biol Sci Med Sci* 67:1427–1438
97. Salkeld G, Cameron ID, Cumming RG, Easter S, Seymour J, Kurrle SE, Quine S (2000) Quality of life related to fear of falling and hip fracture in older women: a time trade off study. *BMJ* 320:341–346
98. Coons SJ, Rao S, Keininger DL, Hays RD (2000) A comparative review of generic quality-of-life instruments. *Pharmacoeconomics* 17:13–35
99. Williams K, Frei A, Vetsch A, Dobbels F, Puhan MA, Rudell K (2012) Patient-reported physical activity questionnaires: a systematic review of content and format. *Health Qual Life Outcomes* 10:28
100. Bowling A, Stenner P (2011) Which measure of quality of life performs best in older age? A comparison of the OPQOL, CASP-19 and WHOQOL-OLD. *J Epidemiol Community Health* 65:273–280
101. Molzahn A, Skevington SM, Kalfoss M, Makaroff KS (2010) The importance of facets of quality of life to older adults: an international investigation. *Qual Life Res* 19:293–298
102. Parmelee PA, Thuras PD, Katz IR, Lawton MP (1995) Validation of the cumulative illness rating scale in a geriatric residential population. *J Am Geriatr Soc* 43:130–137
103. Haywood KL, Garratt AM, Fitzpatrick R (2005) Quality of life in older people: a structured review of generic self-assessed health instruments. *Qual Life Res* 14:1651–1668
104. Hickey A, Barker M, McGee H, O’Boyle C (2005) Measuring health-related quality of life in older patient populations: a review of current approaches. *Pharmacoeconomics* 23: 971–993
105. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 30:473–483
106. EuroQol Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. *The EuroQol Group. Health Policy* 16:199–208
107. Hunt SM, McKenna SP, McEwen J, Backett EM, Williams J, Papp E (1980) A quantitative approach to perceived health status: a validation study. *J Epidemiol Community Health* 34:281–286
108. Hyde M, Wiggins RD, Higgs P, Blane DB (2003) A measure of quality of life in early old age: the theory, development and properties of a needs satisfaction model (CASP-19). *Aging Ment Health* 7:186–194
109. Lawton MP, Moss M, Fulcomer M, Kleban MH (1982) A research and service oriented multilevel assessment instrument. *J Gerontol* 37:91–99
110. De Leo D, Diekstra RF, Lonnqvist J, Trabucchi M, Cleiren MH, Frisoni GB, Dello Buono M, Haltunen A, Zucchetto M, Rozzini R, Grigoletto F, Sampaio-Faria J (1998) LEIPAD, an internationally applicable instrument to assess quality of life in the elderly. *Behav Med* 24:17–27
111. Power M, Quinn K, Schmidt S (2005) Development of the WHOQOL-old module. *Qual Life Res* 14:2197–2214
112. Ware JE Jr (1996) The SF-36 Health Survey. In: Spilker B (ed) *Quality of life and pharmacoeconomics in clinical trials*, 2nd edn. Lippincott-Raven, Philadelphia, pp 337–344
113. Syddall HE, Martin HJ, Harwood RH, Cooper C, Sayer AA (2009) The SF-36: a simple, effective measure of mobility-disability for epidemiological studies. *J Nutr Health Aging* 13:57–62
114. Sayer AA, Syddall HE, Martin HJ, Dennison EM, Roberts HC, Cooper C (2006) Is grip strength associated with health-related quality of life? findings from the herfordshire cohort study. *Age Ageing* 35:409–415
115. Lips P, Cooper C, Agnusdei D, Caulin F, Egger P, Johnell O, Kanis JA, Kellingray S, Leplege A, Liberman UA, McCloskey E, Minne H, Reeve J, Reginster JY, Scholz M, Todd C, de Vernejoul MC, Wiklund I (1999) Quality of life in patients with vertebral fractures: validation of the quality of life questionnaire of the European foundation for osteoporosis (QUALEFFO). working party for quality of life of the European foundation for osteoporosis. *Osteoporos Int* 10:150–160
116. Marquis P, Cialdella P, De la Loge C (2001) Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOST. *Qual Life Res* 10:555–566
117. Randell AG, Bhalariao N, Nguyen TV, Sambrook PN, Eisman JA, Silverman SL (1998) Quality of life in osteoporosis: reliability, consistency, and validity of the osteoporosis assessment questionnaire. *J Rheumatol* 25:1171–1179
118. Osteoporosis Quality of Life Study Group (1997) Measuring quality of life in women with osteoporosis. *Osteoporos Int* 7:478–487
119. Helmes E, Hodsman A, Lazowski D, Bhardwaj A, Crilly R, Nichol P, Drost D, Vanderburgh L, Pederson L (1995) A questionnaire to evaluate disability in osteoporotic patients with vertebral compression fractures. *J Gerontol A Biol Sci Med Sci* 50:M91–M98
120. Lydick E, Zimmerman SI, Yawn B, Kleerekoper M, Ross P, Martin A, Holmes R (1997) Development and validation of a discriminative quality of life questionnaire for osteoporosis (the OPTQoL). *J Bone Miner Res* 12:456–463
121. Vincent KA, Carr AJ, Walburn J, Scott DL, Rose MR (2007) Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). *Neurology* 68:1051–1057
122. Masel MC, Graham JE, Reistetter TA, Markides KS, Ottenbacher KJ (2009) Frailty and health related quality of life in older Mexican Americans. *Health Qual Life Outcomes* 7:70
123. Lin CC, Li CI, Chang CK, Liu CS, Lin CH, Meng NH, Lee YD, Chen FN, Li TC (2011) Reduced health-related quality of life in elders with frailty: a cross-sectional study of community-dwelling elders in Taiwan. *PLoS One* 6:e21841
124. Chang YW, Chen WL, Lin FG, Fang WH, Yen MY, Hsieh CC, Kao TW (2012) Frailty and its impact on health-related quality of life: a cross-sectional study on elder community-dwelling preventive health service users. *PLoS One* 7:e38079
125. Kull M, Kallikorm R, Lember M (2012) Impact of a new sarcopenia definition on health-related quality of life in a population-based cohort in northern Europe. *J Clin Densitom* 15:32–38
126. Gobbens RJ, van Assen MA, Luijckx KG, Schols JM (2012) The predictive validity of the tilburg frailty indicator: disability,

- health care utilization, and quality of life in a population at risk. *Gerontologist* 52:619–631
127. Langlois F, Vu TT, Kergoat MJ, Chasse K, Dupuis G, Bherer L (2012) The multiple dimensions of frailty: physical capacity, cognition, and quality of life. *Int Psychogeriatr* 24:1429–1436
128. Bautmans I, Njemini R, Predom H, Lemper JC, Mets T (2008) Muscle endurance in elderly nursing home residents is related to fatigue perception, mobility, and circulating tumor necrosis factor-alpha, interleukin-6, and heat shock protein 70. *J Am Geriatr Soc* 56:389–396
129. Acree LS, Longfors J, Fjeldstad AS, Fjeldstad C, Schank B, Nickel KJ, Montgomery PS, Gardner AW (2006) Physical activity is related to quality of life in older adults. *Health Qual Life Outcomes* 4:37
130. Motl RW, McAuley E (2010) Physical activity, disability, and quality of life in older adults. *Phys Med Rehabil Clin N Am* 21:299–308
131. Gorby HE, Brownawell AM, Falk MC (2010) Do specific dietary constituents and supplements affect mental energy? Review of the evidence. *Nutr Rev* 68:697–718
132. Fries JF, Cella D, Rose M, Krishnan E, Bruce B (2009) Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing. *J Rheumatol* 36:2061–2066
133. Mokkink LB, Terwee CB, Knol DL, Stratford PW, Alonso J, Patrick DL, Bouter LM, de Vet HC (2006) Protocol of the COSMIN study: Consensus-based Standards for the selection of health measurement instruments. *BMC Med Res Methodol* 6:2
134. Angst F (2011) The new COSMIN guidelines confront traditional concepts of responsiveness. *BMC Med Res Methodol* 11:152
135. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, Ader D, Fries JF, Bruce B, Rose M (2007) The patient-reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two years. *Med Care* 45:S3–S11
136. Khanna D, Krishnan E, Dewitt EM, Khanna PP, Spiegel B, Hays RD (2011) Patient-reported outcomes measurement information system (PROMIS(R))—the future of measuring patient reported outcomes in rheumatology. *Arthritis Care Res (Hoboken)* 63:S486–S490
137. Louie GH, Ward MM (2010) Association of measured physical performance and demographic and health characteristics with self-reported physical function: implications for the interpretation of self-reported limitations. *Health Qual Life Outcomes* 8:84
138. Bijlsma AY, Meskers CG, Westendorp RG, Maier AB (2012) Chronology of age-related disease definitions: osteoporosis and sarcopenia. *Ageing Res Rev* 11:320–324
139. WGFOMCT—Working Group on Functional Outcome Measures in Frail Older Persons (2008) Functional outcomes for clinical trials in frail older persons: time to be moving. *J Gerontol A Biol Sci Med Sci* 63:160–164
140. Committee for Medicinal Products for Human Use (CHMP) (2011) EMA geriatric medicines strategy. EMA/CHMP/137793/2011. [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Other/2011/02/WC500102291.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/02/WC500102291.pdf). Cited 7 Mar 2013
141. Lagiewka K (2012) European innovation partnership on active and healthy ageing: triggers of setting the headline target of two additional healthy life years at birth at EU average by 2020. *Arch Public Health* 70:23